EA004178B1 - Medicament for treating patients suffering from opiomania and method therefor - Google Patents

Abstract

1. An implanted medicament for treating patients suffering from opiomania based on naltrexon, characterized in that further comprises corticosteroid with the following components ratio: naltrexon 50-100 corticosteroid 4-8 2. The medicament of claim 1, characterized in that triamcynolon is used as corticosteroid. 3. A method for treating a patient suffering from opiomania by steps effecting on a patient, wherein in a first step a detoxication is carried out using naloxon and naltrexon under general anesthesia against a background of artificial lung ventilation, then naltrexon-corticosteroid medicament is implanted and followed by psychological rehabilitation of the patient and his circle. 4. The method of claim 3, characterized in that the detoxication lasts for 6 to 7 hours. 5. The method of claims 3 and 4, characterized in that the naltrexon-corticosteroid medicament is implanted in the form of tablets and capsules for 2 to 3 months. 6. The method of claims 3 to 5, characterized in that a remission period is prolonged by a repeated administration of the naltrexon-corticosteroid medicament.

Description

The present invention relates to pharmacy and medicine, in particular to drugs for the treatment of patients with opium addiction and methods for their treatment, which can be used in narcology.

It is known to use tetraethylthiuram disulfide (“Antabus”, “Disulfiram”, tablets for implantation “Radoter” or “Esperal”) for the treatment of drug addiction [1].

The disadvantage of this known means, regardless of the dosage form used, is a relatively low efficacy in the treatment of opium addiction, the presence of a large number of pronounced side effects and a large number of contraindications.

Closest to the proposed remedy is the use for the treatment of opium addiction naltrexone in pill or capsulated form for oral administration [2].

The disadvantage of this tool is its relatively low efficiency, which may be due to the relatively low duration of action and the clinical features of this category of patients.

There is a method of treating patients with opium addiction (dependence on opium, heroin, morphine, methadone, codeine), which provides for the withdrawal of withdrawal syndrome for 7-15 days and the subsequent appointment of naltrexone orally in a daily dose of 50-150 mg with an interval of 1-3 days from 1.5-3 months [2].

The disadvantage of this known method is the relatively low efficiency (the number of patients with remission and its duration), the high degree of physical suffering of the patient ("breaking") and the need for long-term treatment.

The present invention is characterized by the fact that the proposed group of inventions, united by a single inventive concept.

Proposed in accordance with the invention, the medicinal product for the treatment of patients with opium addiction includes naltrexone and corticosteroid in the following ratio of components, weight. including:

Naltrexone 50-100

Corticosteroid 4-8

Triamcinolone is preferred as a corticosteroid.

The drug is used in the form of an implant.

A method for treating patients with opium addiction is that a patient under general anesthesia is artificially ventilated using artificial ventilation using opiate antagonists, such as naloxone and naltrexone, followed by implantation of the drug naltrexone-corticosteroid and psychological rehabilitation of the patient and his immediate environment.

Practically, the method is carried out in three stages as follows:

stage - detoxification - purification of opiate receptors from the drug under general anesthesia against the background of artificial ventilation by opiate antagonists such as naloxone and naltrexone for 6-7 hours;

stage - implantation of the above drug to the patient - naltrexontriamcinolone by the conventional method for 2-3 months. If necessary, repeated implantations are possible depending on the condition of the patient;

stage - psychological rehabilitation of the patient and his immediate environment, aimed at a deeper study of the psychological side of addiction. At this stage, various approved psychological methods are used to help the patient adapt to life without a drug.

The following examples illustrate the proposed drug according to the invention and the method of treatment based on this tool.

1. An example of obtaining tablets for implantation.

To 50 weight.h. naltrexone add 4 weight.h. triamcinolone and a sufficient amount of fillers. The resulting mass is pressed and sterilized.

2. An example of treatment.

Patient K., 18 years old, diagnosed with opium addiction, experience of using heroin for 2 years at a daily dose of 0.5 g. He was twice treated at home and in the hospital at the place of residence using traditional approaches and means. In both cases, the remission period did not exceed 2 weeks. With the consent of the patient and his parents were treated by the proposed method. After a preliminary medical examination, the patient was placed under general anesthesia with mechanical ventilation for a period of 6 hours, during which naltrexone was injected for detoxification. At the 6th hour of the procedure, naltrexone-triamcinolone was implanted subcutaneously to the patient. After 2 days, a course of psychological rehabilitation was started with the patient and his parents, which was carried out for 3.5 months. Subsequent observation of this patient for 9 months showed sustained remission with complete cessation of drug use.

In the treatment of 30 patients with opium addiction according to the proposed method using the proposed remedy, a positive effect with refusal to take the drug for a period of 3-6 months was observed in 24 patients (80%).

When treated in a known manner using oral forms of naltrexone (Antakson, 2athop Stoir or Revia, BiRop!

Ryatt) opium drug addiction patients refusing to take drugs for a similar period was observed only in 5% of cases.

As follows from the above results, the proposed remedy has a prolonged effect and high clinical efficacy, and the method according to the invention allows patients to be relieved of the suffering associated with experiencing withdrawal symptoms and to achieve sustained remission.

Used Books:

1. Mashkovsky M.D. Medicinal products. - Kharkiv: Torsing, 1997.-Ch.1.-C.226-228.

2. Ryu81S1ai8 'Es5k RSGsGspes.- Meb1sa1 Esoposh1S8 Sotrupa, 1998.-E6.52.-R.871.

Claims (6)

1. Implantable drug for the treatment of patients with opiate addiction based on naltrexone, characterized in that it additionally contains a corticosteroid in the following ratio of components, parts by weight: Naltrexone 50-100 Corticosteroid 4-8 2. The drug according to claim 1, characterized in that triamcinolone is used as a corticosteroid. 3. A method of treating a patient with opium addiction by phasing the patient, in the first stage, under general anesthesia and mechanical ventilation, detoxify the body using naloxone and naltrexone, then implant the drug naltrexone-corticosteroid and then conduct psychological rehabilitation of the patient and his inner circle. 4. The treatment method according to claim 3, characterized in that the detoxification of the body is carried out for 6-7 hours 5. The treatment method according to claims 3, 4, characterized in that the drug naltrexoncorticosteroid is implanted in the form of tablets or capsules for a period of 2-3 months. 6. The treatment method according to claims 3-5, characterized in that the timing of remission is lengthened by the repeated administration of the drug naltrexone-corticosteroid.